FDA approves first implantable hearing device
The U.S. Food and Drug Administration approved the first implantable device for people 18 and older with severe or profound sensorineural hearing loss of high-frequency sounds in both ears, but who can still hear low-frequency sounds with or without a hearing aid. The Nucleus Hybrid L24 Cochlear Implant System may help those with this specific kind of hearing loss who do not benefit from conventional hearing aids.

New findings, by group of scientists, will facilitate the development of new clinical strategies design to prevent or treat infections caused by multidrug-resistant Klebsiella Pneumoniae.
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
ABOOUT AUTHORS:
DelCure LifeSciences Ltd. (DLL) is a full scale pharmaceutical company with an aim to bring differentiated high quality products through international collaboration with innovator companies from the USA, Switzerland, and European countries. High quality products are assured from our manufacturing partner of high repute.
Health Management and Research Institute is a registered non-profit organization based in Hyderabad, Andhra Pradesh. HMRI is supported by Piramal Foundation. and works towards making healthcare accessible, affordable and available to all segments of the population, especially those most vulnerable. In order to achieve this goal, HMRI leverages cutting edge information and communication technologies to cut costs without compromising quality as well as public-private partnerships to scale its solutions throughout India and beyond.
The Drugs and Cosmetics Rules, 1945 (D&C rules) were amended vide Drugs and Cosmetics (Fourth Amendment) Rules, 2013 published under Gazette notification G.S.R. 588(E) dated 30.08.2013 regarding the inclusion of Schedule H1 under the D&C rules containing certain antibiotics, anti-TB drugs and habit forming drugs. The notification states that these rules will come into force after six months of their publication in the official Gazette i.e. from 1st March, 2014


